NCT05553509

Brief Summary

Observe Timing to complete healing of wounds \& Limb salvage in both cohorts those who are undergoing Debridement only and those who are undergoing Debridement plus PTA

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 23, 2022

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2024

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

November 26, 2024

Status Verified

November 1, 2024

Enrollment Period

1.8 years

First QC Date

September 19, 2022

Last Update Submit

November 25, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Clinical Outcomes Following Surgical Debridement of Diabetic Foot Infection With Borderline Vascularity

    1. Observe the timing to complete wound healing in both cohorts those with Debridement only \& those with Debridment plus PTA 2. Observe the Rate of limb salvage in both groups

    1 YEAR

Secondary Outcomes (1)

  • Clinical Outcomes Following Surgical Debridement of Diabetic Foot Infection With Borderline Vascularity

    1 YEAR

Study Arms (2)

ANGIOPLASTY GROUP

All patients undergoing PTA are going to be classified according to GLASS staging system

Other: PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY

DEBRIDEMENT GROUP

The most commonly used technique for diabetic foot ulcers is sharp or surgical debridement using a scalpel, tissue forceps or similar instruments. It should be sufficiently extensive to remove all infected and necrotic tissue;

Other: PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY

Interventions

SURGICAL DEBRIDEMNT

Also known as: REVASCULARIZATION
ANGIOPLASTY GROUPDEBRIDEMENT GROUP

Eligibility Criteria

Age30 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

On the other hand we can consider patients as Borderline ischemia/ Boarderline Vascularity with (Rutherford Grade "I" Categories "2\&3) when they have a borderline ankle systolic pressure

You may qualify if:

  • Patients will be included in this study are those suffering from DFUs; and Borderline Ischemia (BLI) / Borderline Vacularity with (Rutherford Grade "I" Categories "2\&3") when they have a borderline ankle systolic pressure

You may not qualify if:

  • All patients with (CLI) and DFUs as they are indicated for urgent re-vascularization.
  • Severely infected/ gangrenous wounds requiring amputation hindering possible limb salvage.
  • Lesions lying within or adjacent to an aneurysm; Non diabetic cases with foot ulcers; Arteritic lesions;(Vasculitic Patients). Patients had prior major amputation, bypass surgery, and endarterectomy on any vessel of the ipsilateral (target) extremity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of vascular surgery - Assiut University Hospital

Asyut, Asyut Governorate, 71515, Egypt

Location

MeSH Terms

Conditions

Chronic Limb-Threatening Ischemia

Condition Hierarchy (Ancestors)

Peripheral Arterial DiseaseAtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsIschemia

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

September 19, 2022

First Posted

September 23, 2022

Study Start

January 1, 2023

Primary Completion

November 1, 2024

Study Completion

September 1, 2025

Last Updated

November 26, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations